Tuesday, September 3, 2013

Safety committee raises concern over ArQule's liver cancer drug

(Reuters) - Drugmaker ArQule Inc said a late-stage trial of its liver cancer drug showed high incidence of low white blood cell count in patients, leading to an independent safety committee recommending the company lower the drug dose.

No comments:

Post a Comment

Subscribe Now: Feed Icon